WDA
REGN icon

Wendell David Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Wendell David Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-415
Closed -$204K – 159
2017
Q2 		$204K Buy
+415
New +$182K 0.04% 143
2016
Q1 		– Sell
-455
Closed -$247K – 148
2015
Q4 		$247K Hold
455
– – 0.05% 141
2015
Q3 		$212K Hold
455
– – 0.04% 146
2015
Q2 		$232K Buy
455
+10
+2% +$4.88K 0.05% 145
2015
Q1 		$201K Buy
+445
New +$189K 0.04% 148

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Wendell David Associates's REGN Position: Q3 2017 in Review

Wendell David Associates sold out of Regeneron Pharmaceuticals (REGN) in Q3 2017, closing a stake of 415 shares — an estimated $204K sold.

Wendell David Associates first reported a position in REGN in Q1 2015 and held it in 5 quarters. The position peaked at $247K in Q4 2015. 606 funds tracked by Wall St. Rank hold REGN as of Q3 2017.

  • Wendell David Associates reported no remaining Regeneron Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Wendell David Associates sold 415 Regeneron Pharmaceuticals shares in Q3 2017, an estimated $204K.
  • Wendell David Associates first reported a position in Regeneron Pharmaceuticals in Q1 2015 and held it in 5 quarters.
  • Wendell David Associates's Regeneron Pharmaceuticals position peaked at $247K in Q4 2015.
  • 606 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2017.

Based on Wendell David Associates's 13F filing for Q3 2017, filed 17 Oct 2017.